Prosecution Insights
Last updated: October 02, 2026
Application No. 18/902,199

NON-SHEDDING COUPLING METHOD AND SYSTEM FOR RELOADABLE HEMOSTASIS CLIP

Non-Final OA §DOUBLEPATENT
Filed
Sep 30, 2024
Priority
Jul 24, 2019 — provisional 62/877,879 +2 more
Examiner
LABRANCHE, BROOKE N
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Boston Scientific Corporation
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
1y 0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
343 granted / 472 resolved
+2.7% vs TC avg
Strong +16% interview lift
Without
With
+15.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
74 currently pending
Career history
544
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
44.7%
+4.7% vs TC avg
§102
31.1%
-8.9% vs TC avg
§112
20.3%
-19.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 472 resolved cases

Office Action

§DOUBLEPATENT
CTNF 18/902,199 CTNF 93622 DETAILED ACTION Notice of Pre-AIA or AIA Status 07-03-aia AIA 15-10-aia The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Examiner Note In the interest of compact prosecution, Examiner attempted to contact Applicant to request filing of an eTD in order to place the claims in condition for allowance. No response was received. Double Patenting 08-33 AIA The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg , 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman , 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi , 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum , 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel , 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington , 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 08-34 AIA Claim 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, and 51 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 1, 10, 11, 12, 13, 16, and 17 respectively of U.S. Patent No. 11,690,634 . Although the claims at issue are not identical, they are not patentably distinct from each other because the scope of the patent claims is narrower and therefore anticipates the broader application claims . Regarding claim 36, U.S. Patent No. 11,690,634 discloses a clipping system for treating tissue, comprising (col 10 line 33) :a clipping apparatus including clip arms (col 10 line 34) slidably received in a capsule (col 10 line 36-37), the capsule including a window extending through a proximal end thereof (col 10 line 38-40; wherein window and openings extending through the wall are equivalent); a coupler mounted over the proximal end of the capsule (col 10 line 41), the coupler including a retention arm having a retaining feature and a deployment arm having an engaging feature configured to be received within the windows of the capsule (col 10 lines 42-45); and a distal end of an applicator including a projection extending about a periphery thereof, the projection configured to be engaged by the retaining feature to couple the coupler to the distal end (col 10 lines 51-55), and the deployment arm being configured so that, when a compressive force exerted on the coupler exceeds a predetermined threshold, the deployment arm slides proximally along the projection and deflects radially outward to disengage the engaging feature from the capsule so that the coupler separates from the capsule while remaining coupled to the distal end (col 10 line 55-63). Regarding claim 48, U.S. Patent No. 11,690,634 discloses a clip device for treating tissue (col 12 line 1), comprising: a clipping apparatus including clip arms (col 12 line 2) slidably received in a capsule (col 12 liens 3-5), the capsule including a window extending through a proximal end thereof (col 12 lines 6-8); and a coupler mounted over the proximal end of the capsule via a deployment arm (col 12 lines 9-10) including an engaging feature extending laterally inward from an interior surface thereof to engage the window of the capsule (col 12 lines 10-13), the coupler including a retention arm having a retaining feature configured to engage a distal end of an applicator to couple the coupler to the distal end (col 12 lines 13-15; where distal end and bushing are equivalent structures), the deployment arm being configured so that, when a compressive force exerted on the coupler exceeds a predetermined threshold, the deployment arm slides proximally along a projection extending about a periphery of the distal end and deflects radially outward to disengage the engaging features from the capsule so that the coupler separates from the capsule while remaining coupled to the distal end (col 12 lines 14-21) . 07-30-03-h AIA Claim Interpretation 07-30-03 AIA The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. 07-30-05 The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. 07-30-06 This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “retaining feature” and “engaging feature” in claims 36, 40, 45, 48, 50, and 52. [0046-0047] of the specification of the present invention identify the “retention feature” as being a laterally extending protrusion. [0048-0051] of the specification of the present invention identify the “engaging feature” as being a laterally extending protrusion. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BROOKE N LABRANCHE whose telephone number is (571)272-9775. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth Houston can be reached at 5712727134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BROOKE LABRANCHE/ Primary Examiner, Art Unit 3771 Application/Control Number: 18/902,199 Page 2 Art Unit: 3771 Application/Control Number: 18/902,199 Page 3 Art Unit: 3771 Application/Control Number: 18/902,199 Page 4 Art Unit: 3771 Application/Control Number: 18/902,199 Page 5 Art Unit: 3771 Application/Control Number: 18/902,199 Page 6 Art Unit: 3771 Application/Control Number: 18/902,199 Page 7 Art Unit: 3771 Application/Control Number: 18/902,199 Page 8 Art Unit: 3771
Read full office action

Prosecution Timeline

Sep 30, 2024
Application Filed
May 04, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740799
DIRECTABLE TRACTION SYSTEMS AND METHODS
1y 9m to grant Granted Sep 22, 2026
Patent 12727963
INTEGRATED RFID TAG IN A MANUAL INSTRUMENT
2y 11m to grant Granted Sep 08, 2026
Patent 12727956
END TOOL FOR SURGICAL INSTRUMENT
1y 11m to grant Granted Sep 08, 2026
Patent 12708397
REPLACEABLE SURGICAL SCISSOR BLADES FOR SURGICAL INSTRUMENTS
2y 7m to grant Granted Aug 18, 2026
Patent 12702394
DEVICES, SYSTEMS, AND METHODS FOR TREATING THE LEFT ATRIAL APPENDAGE
5y 1m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
88%
With Interview (+15.7%)
3y 0m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 472 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month